New Lung Cancer Considered Episode with Narjust Florez and Julia Rotow
Florez Lab shared a post on X:
“FDA approved lazertinib + amivantamab for first-line treatment of advanced NSCLC with EGFR mutations.
In Lung Cancer Considered, Dr. Narjust Florez chats with Dr. Julia Rotow from Dana-Farber about this therapy and the MARIPOSA trial.
Source: Florez Lab/X
Narjust Florez is the Associate Director of the Cancer Care Equity Program and a Thoracic Medical Oncologist at the Dana-Farber Brigham Cancer Center. She is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study, the largest study to date evaluating sexual dysfunction in women with lung cancer. In addition, Dr. Florez founded the Florez Lab in 2019. The laboratory focuses on lung cancer, social justice issues in medicine, and medical education.
Julia Rotow is a Medical Oncologist, Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute. She completed her residency from Massachusetts General Hospital and was a Predoctoral Fellow at HHMI-NIH Research Scholars. She earned her B.A. from Harvard University.